AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.
AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.